Merck Pharma holding hands with Ali Health Path-to-Road Pharmaceutical e-commerce

On June 20, Merck Pharma and Ali Health signed a strategic partnership framework agreement to create patient-centric digital health services that bring more medical and health services to patients and their families in China. At the signing ceremony held in Shanghai, the two sides announced that they will cooperate in drug traceability, Internet health services and other fields, and actively explore in the fields of pharmaceutical e-commerce and artificial intelligence.
It is understood that this cooperation will be the first to launch in Ali Health's "code rest assured" traceability platform, based on Merck's advantages in the field of diabetes, thyroid and cardiovascular, relying on Ali Health in the field of Internet medicine and health, to promote patient safety medication, while providing patients with a range of value-added services. The two companies will continue to promote the use of Internet medical and health services, exploring direct patient medicine services (DTP model) and artificial intelligence health applications.
" Ali Health and Merck cooperation is the inevitable result of the development of the times, I am full of expectations for the collision of the two companies. "China is going through a profound process of Internet transformation, and the Internet will permeate every aspect of industrial production, business operations and people's daily lives in the future," said Shen Difan, CEO of Ali Health. Because of the particularity and importance of the medical and health sector, the convergence of the Internet and traditional industries also requires industry leader to lead the way. Ali Health's cooperation with Merck in Germany, on the one hand, can enrich the connotation of its own platform, on the other hand, it is also expected that Ali Health's technical advantages can provide a catalyst for the sustainable development of the "100-year-old shop." "
" Our vision for China is to improve the lives of 40 million patients in China by 2025. Digitalization is an important part of our vision for China. Roger Ren, Managing Director of Merck China Biopharmaceuticals, said, "Merck's products cover areas such as chronic diseases, reproduction and oncology, and have a medical team with expertise in these areas, combined with Ali Health's cutting-edge Internet technology tools and experience, the cooperation between the two sides will effectively improve the level of disease awareness and health management of Chinese patients." In recent
, in order to promote the reform of the health care system, the state has introduced a series of comprehensive policy initiatives. As a national priority development strategy, "Healthy China 2030" is the first long-term strategic plan in the field of health proposed at the national level, establishing a "great health concept" and "big health view" "to promote health as the center", and actively promoting China's economy and society to "invest in health". In order to meet the people's growing multi-level diversified medical and health needs, in April this year, the General Office of the State Council issued the Opinions on Promoting the Development of "Internet plus Medical Health", which is another heavyweight top-level design in the field of Internet medical care following the central deployment and development of "Internet plus Medical".
faced with these policy dividends, Merck said it would move steadily into the digital age with an open mind and vigorously expand access to medical health, edging out the Internet plus model.
, Merck focuses on three areas: pharmaceutical health, life sciences, and high-performance materials, according to public data released by the company. From biotherapy for cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystal materials for smartphones and flat-screen TVs. In 2017, Merck's total sales in 66 countries amounted to EUR 15.3 billion. In addition, Merck has been deep in China for 85 years, Merck China Pharmaceutical Health business operates 16 drugs in 7 major diseases, advanced technology in the field of reproductive and thyroid therapy, in the field of cardiovascular, endocrine and oncology is also in the industry leader. And Ali Health (00241. HK) is Alibaba Group's "Double H" strategy (Health and Happiness) flagship platform in the field of medical and health, Alibaba Group is one of the investment holding companies. At present, Ali Health's business is mainly focused on pharmaceutical e-commerce, smart medical, product traceability and other fields. (Economic Watch Network)